Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Forest Labs Posts Weak Quarter
TheStreet.com
Tuesday, October 18, 2011 - 10:33am
tags:
earnings, Forest Labs
FDA Panel: Teva Parkinson's Drug Doesn't Slow Disease
NASDAQ.com
Tuesday, October 18, 2011 - 9:26am
tags:
FDA, advisory panels, Teva Pharmaceuticals, Parkinson's Disease, Azilect
Embryonic Stem-Cell Patents Infringe EU Law, Top Court Says
Bloomberg
Tuesday, October 18, 2011 - 9:24am
tags:
embryonic stem cells, Europe, stem cells
Third Rock Ventures launches new biotech, SAGE Therapeutics
Bizjournals.com
Tuesday, October 18, 2011 - 9:23am
tags:
SAGE Therapeutics, Third Rock, CNS
5 Top Birth Control Stocks To Hold As Contraception Skyrockets Due to Recession
Seeking Alpha
Tuesday, October 18, 2011 - 9:01am
tags:
contraceptives, birth control, JNJ, Merck, Pfizer, Teva Pharmaceuticals
J&J Third-Quarter Profit Declines on Generics
Bloomberg
Tuesday, October 18, 2011 - 9:00am
tags:
earnings, generics, JNJ
Astra, Forest to start Phase 3 superbug drug study
Reuters
Tuesday, October 18, 2011 - 8:59am
tags:
AstraZeneca, Forest Labs, CAZ-AVI, antibiotics, superbugs
Anadys acquisition sign of more to come
The Deal
Tuesday, October 18, 2011 - 8:53am
tags:
Anadys, Roche, Merck, JNJ, Achillion, M&A, Indenix, Bristol-Myers Squibb
The 8 Highest Potential Returns in Biotechnology
Motley Fool
Monday, October 17, 2011 - 7:33pm
tags:
Biomarin, Emergent BioSolutions, United Therapeutics, Gilead, 3SBio, Targacept, Amgen, Celgene
Earnings Preview: Abbott to report 3Q earnings
Yahoo/AP
Monday, October 17, 2011 - 7:31pm
tags:
Abbott Laboratories, earnings
Par Pharma sues FDA, claiming free speech rights
Fierce Pharma
Monday, October 17, 2011 - 7:31pm
tags:
FDA, lawsuits, free speech, Par Pharmaceutical, off-label, Allergan
Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market
TheStreet.com
Monday, October 17, 2011 - 1:22pm
tags:
Roche, M&A, Anadys, hepatitis C, Pegasys, setrobuvir, Merck, Victrelis, RG7128, Pharmasset
Infinity advances pancreatic cancer drug candidate
Bizjournals.com
Monday, October 17, 2011 - 1:20pm
tags:
Infinity, pancreatic cancer, IPI-926
With Earnings Around The Corner, Human Genome Continues To Drop
Seeking Alpha
Monday, October 17, 2011 - 12:09pm
tags:
earnings, Human Genome Sciences
Sequenom to Sell Down Syndrome Test 2 Years After Pullback
Bloomberg
Monday, October 17, 2011 - 12:08pm
tags:
Sequenom, Downs Syndrome
Watson Files ANDAs
Yahoo/Zacks.com
Monday, October 17, 2011 - 12:07pm
tags:
Watson Pharmaceuticals, Momenta, Noven, Daytrana, Pfizer, Embeda, Novartis, Sanofi, Lovenox
Eli Lilly & Co. Third Quarter Earnings Sneak Peek
Yahoo/Wall St. Cheat Sheet
Monday, October 17, 2011 - 12:05pm
tags:
Eli Lilly, earnings
Vertex Declines After Sales of Incivek Are Little Changed
Bloomberg
Monday, October 17, 2011 - 12:04pm
tags:
Vertex, Incivek, hepatitis C
KV Pharma Sues Former CEO Over $37M In Benefits
Pharmalot
Monday, October 17, 2011 - 9:37am
tags:
KV Pharmaceutical, Mark Hermelin
Vivus Resubmits Qnexa Obesity Drug After Birth-Defect Warning
Bloomberg
Monday, October 17, 2011 - 9:30am
tags:
warnings, Vivus, Qnexa, FDA, obesity

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.